Breaking Barriers in Science: The Women of DoubleRainbow Biosciences
2022: The year of acceleration
Double Rainbow ramps up production of ancient natural painkiller
Double Rainbow Announces World’s First Commercial-Scale Biosynthetic Gastrodin, a Natural Analgesic with a Range of Therapeutic Applications
Double Rainbow Announces Membership with BioMADE
Big Pharma’s Green Ambitions
Kelai pens Double Rainbow pact to pair drug delivery and biosynthesis tech
DoubleRainbow Biosciences and Kelai Pharmaceuticals to collaborate on novel natural compound therapeutics
Cutting the carbon footprint of pharma’s supply chain
Could Sugar Hold the Key to Cancer?
Pharma Sets a Foundation for Greener API Manufacturing
Is Poor Bioavailability Holding Back Modern Medicine?
